Ischemia and reperfusion injury combined with cisplatin induces immunogenic cell death in lung cancer cells

A first-line chemotherapeutic drug for non-small cell lung cancer (NSCLC), cisplatin (CDDP), fails to induce immunogenic cell death (ICD) because it fails to induce calreticulin (CRT) exposure on the cell surface. We investigated the potential of ischemia and reperfusion injury (I/R) combined with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shuai, Li, Yumei, Liu, Shuqing, Ma, Pei, Guo, Mengfei, Zhou, E., Duan, Limin, Fan, Jinshuo, Liao, Tingting, Tan, Qi, Wang, Xuan, Wu, Feng, Jin, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440929/
https://www.ncbi.nlm.nih.gov/pubmed/36057637
http://dx.doi.org/10.1038/s41419-022-05176-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440929/
https://www.ncbi.nlm.nih.gov/pubmed/36057637
http://dx.doi.org/10.1038/s41419-022-05176-y

Ejemplares similares